Access Dermatology

Latest Clinical Trials

• Alefacept in psoriasis

  Summary

  Sustained long-term remission of chronic plaque psoriasis upon treatment with multiple courses of alefacept

• Infliximab in ankylosing spondylitis: The ASSERT (Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy) & IMPACT II (Infliximab Multinational Psoriatic Arthritis Controlled Trials)

  Summary

  The effect of infliximab on inflammation and bone formation biomarkers and associations with clinical response in ankylosing spondylitis and psoriatic arthritis

• Infliximab in psoriasis: The EXPRESS II (Evaluation of Infliximab for Psoriasis Efficacy and Safety Study)

  Summary

  Infliximab for the treatment of moderate to severe psoriasis: Response to retreatment after 16 weeks or more between infusions

• Etanercept in psoriasis: The EASE (Etanercept Assessment of safety and Effectiveness) study

  Summary

  A retrospective study to investigate ethnic variations in the treatment of psoriasis with etanercept

• Certolizumab in psoriasis

  Summary

  Safety and efficacy (PASI 90 and global evaluation) of subcutaneous certolizumab pegol in patients with moderate to severe chronic plaque psoriasis: Results from a double-blind, placebo-controlled trial

• Vapitadine in atopic dermatitis

  Summary

  Oral vapitadine, a new non-sedating anti-histamine, relieves itch associated with atopic dermatitis

• Apremilast in psoriasis

  Summary

  A phase 2 study demonstrating the efficacy and safety of the oral therapy CC-10004 in subjects with moderate to severe psoriasis

• Apremilast in psoriasis: The PSOR-003 (Double-Blind, Randomized, Placebo-Controlled Comparison of CC10004 in Subjects With Moderate to Severe Plaque Type Psoriasis; NCT00606450) study

  Summary

  Double-blind, randomized, placebo-controlled comparison of CC10004 in subjects with moderate to severe plaque type psoriasis (PSOR-003) (NCT00606450)

• Riluzole vs. corticosteroid in psoriasis

  Summary

  Biofrontera initiates a phase II study for psoriasis

• Dom-0200 in psoriasis/rheumatoid arthritis

  Summary

  Arana announces phase II trials for lead compound ART-621